Biopharma · FDA Approvals · Stock

AVTX Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisoval…

Assets on file: AVTX-009, AVTX-010

Start live analysis of AVTX Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for AVTX, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for AVTX, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Jun 16, 2026

11:18 AM

AVTXAvalo Therapeutics

Avalo Therapeutics plans AVTX-010 IND submission for H1 2027

Avalo announced the addition of AVTX-010, a long-acting anti-IL-1β monoclonal antibody, to its pipeline. The company plans to submit an IND application for AVTX-010 in the first half of 2027, enabling first-in-human studies. This expands the pipeline beyond abdakibart and strengthens the company's IP position.

Application submittedSEC 8-K

Dec 2, 2025

11:38 AM

AVTXAvalo Therapeutics

AVTX-009 Phase 2 LOTUS trial in HS: topline data expected Q2 2026

Avalo completed enrollment in the Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa. Topline results are now guided for Q2 2026, establishing the next regulatory/clinical milestone for the asset.

Topline resultsSEC 8-K Open record2 updates

Oct 10, 2025

11:01 AM

AVTXAvalo Therapeutics

AVTX-009 Phase 2 LOTUS trial in HS enrolling; topline mid-2026

Avalo disclosed that its Phase 2 LOTUS trial (AVTX-009-HS-201, NCT06603077) in hidradenitis suppurativa is now enrolling. Topline data are expected mid-2026, providing the first clinical readout for AVTX-009 in HS.

Trial registry changeSEC 8-K